AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01782547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
Study NCT02325986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Study NCT02325986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Study NCT02325986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Study NCT01788046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Study NCT01788046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously (IV) three times per week.
Study NCT01691274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, 300 mg, single, 1 day
Study NCT01691274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, 300 mg, twice a day, 14 days
Study NCT01691274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, to be decided, twice a day, 14 days
Study NCT01691274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, twice a day, 14 days
Study NCT03463174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture
Description: Placement of an implant in the mandibular midline.
Study NCT03463174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular complete denture
Description: No intervention.
Study NCT01415895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Clonidine Combination
Description: subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Study NCT01415895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Study NCT02765269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Pain Management System
Description: A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
Study NCT02100800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR and CT measurements of emphysema quantification
Study NCT02100800 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MR and CT measurements of emphysema quantification
Study NCT01364077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
Study NCT01364077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00844584 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: epicardial radiofrequency ablation
Description: epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
Study NCT00804622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine
Description: daily oral administration,600mg,over 12 weeks
Study NCT00804622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disproxil fumarate
Description: daily oral administration,300mg,over 12 weeks
Study NCT00804622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine plus tenofovir disproxil fumarate
Description: daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
Study NCT02175628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient.
Study NCT02869074 — intervention group
Intervention type: GENETIC
Intervention: VWF gene analysis
Description: 52 exons adjacent intronic regions and promotor of VWF will be analyzed
Study NCT04362319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire forms
Description: Assessment of demographics, burnout, depression and self-perceived medical errors
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-L-asparaginase
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: see detailed protocol description
Study NCT01662934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I RUNE
Study NCT01662934 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Study NCT00830037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron
Description: IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
Study NCT00830037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
Study NCT03650712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: see detailed protocol description
Study NCT03650712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
Study NCT03650712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dexa scan
Description: low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
Study NCT02761993 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266
Description: 1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
Study NCT02301858 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genome analysis of tissue samples.
Description: Genome analysis of tissue samples.
Study NCT02664987 — intervention group
Intervention type: OTHER
Intervention: Patients receiving cancer pain treatment
Study NCT02761993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
Study NCT00843310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid)
Study NCT00843310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00843310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01905397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound therapy
Description: Sterile bandages and wound coverings
Study NCT03941834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: BHV3000 (rimegepant) 75mg tablet
Study NCT03941834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04433494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg
Description: TY-302 is taken orally. Tamoxifen is taken orally.
Study NCT01029509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB 31121
Description: Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
Study NCT03785938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Liquid probiotic supplied by the company Symprove
Study NCT03785938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo made of maltdextrin. Will be similar in taste and consistency
Study NCT02601027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) block
Study NCT02601027 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane (TAP) block
Study NCT02601027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimbus Infusion Pump IV Administration
Study NCT02601027 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nimbus Infusion Pump IV Administration
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetominophen
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Study NCT01587560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PyroTITAN, Ascension Orthopedics, Inc.
Description: All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
Study NCT01587560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TITAN, Ascension Orthopedics, Inc.
Study NCT03856918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 3 cm of water
Description: PEEP of 3 cm of water will be applied during one-lung ventilation.
Study NCT03856918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 6 cm of water
Description: PEEP of 6 cm of water will be applied during one-lung ventilation.
Study NCT03856918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 9 cm of water
Description: PEEP of 9 cm of water will be applied during one-lung ventilation.
Study NCT03282916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir hydrochloride 500mg caplet
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: see detailed protocol description
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study NCT03438006 — intervention group
Intervention type: OTHER
Intervention: Safety data collection (following routine vaccination)
Description: This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician.
Study NCT02601027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Study NCT03254290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA
Description: A new formulation of MTA was developed in which bismuth oxide was omitted.
Study NCT03254290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: Control group
Study NCT02435316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case vignette-based teaching of cell recognition
Description: Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
Study NCT03254290 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Control group
Study NCT01365247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
Description: A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
Study NCT01365247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Treatment
Description: Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
Study NCT01365247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Monitoring Control Group
Description: Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
Study NCT03242889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARA SC
Description: Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
Study NCT03656107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
Study NCT02435316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compare-contrast basic science teaching of cell recognition
Description: The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
Study NCT04915027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a usual follow-up with Rehabkompassen®
Description: Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
Study NCT04915027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®
Description: Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
Study NCT03420625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot IPC
Description: Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
Study NCT03420625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid calf IPC
Description: Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
Study NCT03420625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slow calf IPC
Description: Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
Study NCT03282916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill 500mg caplet
Study NCT03183947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day
Study NCT03183947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
Study NCT03183947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
Study NCT03183947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BDI-II
Description: to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview